Articles

UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (2617) 2617
science & technology (2598) 2598
life sciences & biomedicine (2516) 2516
male (1314) 1314
pharmacology & pharmacy (1226) 1226
hydroxymethylglutaryl-coa reductase inhibitors - therapeutic use (1221) 1221
statins (1141) 1141
female (1017) 1017
biological and medical sciences (950) 950
medical sciences (916) 916
animals (817) 817
hydroxymethylglutaryl-coa reductase inhibitors - pharmacokinetics (805) 805
hydroxymethylglutaryl-coa reductase inhibitors - pharmacology (802) 802
hydroxymethylglutaryl-coa reductase inhibitors - adverse effects (790) 790
middle aged (735) 735
pharmacology. drug treatments (653) 653
drug interactions (596) 596
hydroxymethylglutaryl-coa reductase inhibitors - administration & dosage (594) 594
aged (587) 587
adult (575) 575
cholesterol (473) 473
cardiovascular system & cardiology (434) 434
risk factors (427) 427
simvastatin (394) 394
treatment outcome (356) 356
hypercholesterolemia - drug therapy (350) 350
abridged index medicus (341) 341
cardiac & cardiovascular systems (341) 341
lipids (339) 339
atorvastatin calcium (332) 332
cholesterol, ldl - blood (311) 311
atorvastatin (308) 308
drug therapy (306) 306
analysis (296) 296
dose-response relationship, drug (293) 293
general and cellular metabolism. vitamins (267) 267
rats (266) 266
medicine & public health (265) 265
drug therapy, combination (250) 250
rosuvastatin calcium (246) 246
research (245) 245
cardiovascular disease (236) 236
cardiovascular diseases (234) 234
pharmacokinetics (230) 230
antilipemic agents (225) 225
statin (224) 224
anticholesteremic agents - therapeutic use (217) 217
cardiovascular diseases - prevention & control (216) 216
general & internal medicine (215) 215
area under curve (214) 214
hypercholesterolemia (207) 207
hydroxymethylglutaryl-coa reductase inhibitors (202) 202
atherosclerosis (200) 200
pharmacology/toxicology (200) 200
dyslipidemias - drug therapy (198) 198
medicine, general & internal (195) 195
hydroxymethylglutaryl-coa reductase inhibitors - blood (194) 194
cardiology (185) 185
rosuvastatin (184) 184
cholesterol - blood (182) 182
care and treatment (175) 175
health aspects (172) 172
hyperlipidemias - drug therapy (171) 171
internal medicine (171) 171
muscular diseases - chemically induced (171) 171
simvastatin - pharmacology (171) 171
aged, 80 and over (170) 170
dosage and administration (167) 167
administration, oral (163) 163
low density lipoproteins (160) 160
pharmacogenetics (159) 159
cardiovascular agents (158) 158
peripheral vascular disease (157) 157
biochemistry & molecular biology (155) 155
pharmacology (155) 155
cross-over studies (154) 154
mice (154) 154
pravastatin (153) 153
nutritional and metabolic diseases (152) 152
time factors (152) 152
lipids - blood (151) 151
heptanoic acids - pharmacology (148) 148
chemistry (147) 147
clinical trials as topic (147) 147
simvastatin - therapeutic use (147) 147
drugs (146) 146
clinical trials (145) 145
enzymes (145) 145
pyrroles - pharmacology (145) 145
physical sciences (144) 144
heptanoic acids - pharmacokinetics (141) 141
hypolipidemic agents - therapeutic use (141) 141
simvastatin - administration & dosage (140) 140
hydroxymethylglutaryl-coa reductase inhibitors - metabolism (139) 139
pyrroles - pharmacokinetics (136) 136
simvastatin - pharmacokinetics (135) 135
physiological aspects (134) 134
toxicology (133) 133
fluvastatin (132) 132
coronary heart disease (131) 131
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (3023) 3023
Japanese (27) 27
German (17) 17
Spanish (14) 14
French (13) 13
Portuguese (10) 10
Russian (10) 10
Chinese (4) 4
Polish (4) 4
Czech (3) 3
Dutch (2) 2
Italian (2) 2
Finnish (1) 1
Hebrew (1) 1
Hungarian (1) 1
Norwegian (1) 1
Swedish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Drug-drug interactions between HMG-CoA reductase inhibitors (statins) and antiviral protease inhibitors
by Chauvin, Benoit and Drouot, Sylvain and Barrail-Tran, Aurélie and Taburet, Anne-Marie
Clinical pharmacokinetics, ISSN 0312-5963, 10/2013, Volume 52, Issue 10, pp. 815 - 831
Life Sciences & Biomedicine | Pharmacology & Pharmacy | Science & Technology | Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage | Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacokinetics | Drug Interactions | Antiviral Agents - pharmacokinetics | Hepatitis C - drug therapy | Hepatitis C - metabolism | Protease Inhibitors - pharmacokinetics | Humans | Protease Inhibitors - administration & dosage | HIV Infections - drug therapy | Antiviral Agents - administration & dosage | HIV Infections - metabolism
Journal Article
Details down arrow
2. Full Text Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: Drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions
by Shitara, Yoshihisa and Sugiyama, Yuichi
Pharmacology & therapeutics (Oxford), ISSN 0163-7258, 10/2006, Volume 112, Issue 1, pp. 71 - 105
Drug-drug interaction | Metabolism | Transporter | HMG-CoA reductase inhibitor | Life Sciences & Biomedicine | Pharmacology & Pharmacy | Science & Technology | Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacokinetics | Animals | Drug Interactions | Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacology | Models, Biological | Humans | Cytochrome P-450 Enzyme System - metabolism | Membrane Transport Proteins - metabolism | Drug resistance in microorganisms | Coenzymes | Thiols | Polypeptides | Low density lipoproteins | Questions and answers | Drug interactions | Cytochrome P-450 | Anticholesteremic agents | Permeability | Antilipemic agents | Hypercholesterolemia | Analysis | Physiological aspects | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Pharmacodynamics and Pharmacokinetics of the HMG-CoA Reductase Inhibitors
: Similarities and Differences
by Lennernäs, Hans and Fager, Gunnar
Clinical pharmacokinetics, ISSN 0312-5963, 5/1997, Volume 32, Issue 5, pp. 403 - 425
Pharmacotherapy | Internal Medicine | Medicine & Public Health | Pharmacology/Toxicology | Life Sciences & Biomedicine | Pharmacology & Pharmacy | Science & Technology | Biological and medical sciences | Medical sciences | General and cellular metabolism. Vitamins | Pharmacology. Drug treatments | Arteriosclerosis - etiology | Lovastatin - therapeutic use | Arteriosclerosis - drug therapy | Lovastatin - pharmacokinetics | Food-Drug Interactions | Humans | Liver - metabolism | Simvastatin | Lovastatin - analogs & derivatives | Enzyme Inhibitors - therapeutic use | Hypercholesterolemia - drug therapy | Brain - metabolism | Anticholesteremic Agents - pharmacokinetics | Anticholesteremic Agents - therapeutic use | Fatty Acids, Monounsaturated - therapeutic use | Enzyme Inhibitors - pharmacokinetics | Fatty Acids, Monounsaturated - pharmacokinetics | Hypercholesterolemia - complications | Indoles - pharmacokinetics | Indoles - therapeutic use | Hydroxymethylglutaryl-CoA Reductase Inhibitors | Pravastatin - therapeutic use | Pravastatin - pharmacokinetics | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Evaluation of interconversion pharmacokinetics of 16α-hydroxycleroda-3,13(14)Z-dien-15,16-olide - a novel HMG-CoA reductase inhibitor and its acid metabolite using multi-compartmental pharmacokinetic model in mice
by Laxman, Tulsankar Sachin and Puttervu, Santosh Kumar and Mishra, Anjali and Verma, Sarvesh and Singh, S. P and Sashidhara, K. V and Marandi, C. M and Saxena, Shivani and Yadav, Manoj K and Bhatta, Rabi S
Xenobiotica, ISSN 0049-8254, 04/2019, Volume 49, Issue 4, pp. 474 - 483
4655K-09 | interconversion parameters | multi-compartmental interconversion model | lactone-acid interconversion | lactone–acid interconversion | Pharmacology & Pharmacy | Toxicology | Life Sciences & Biomedicine | Science & Technology | Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage | Reproducibility of Results | Injections, Intravenous | Administration, Oral | Hydroxymethylglutaryl-CoA Reductase Inhibitors - blood | Metabolome | Male | Hydroxymethylglutaryl-CoA Reductase Inhibitors - chemistry | Diterpenes - pharmacokinetics | Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacokinetics | Animals | Diterpenes - administration & dosage | Time Factors | Models, Biological | Mice | Diterpenes - blood | Diterpenes - chemistry | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Structural Modification of Natural Product Ganomycin I Leading to Discovery of a α‑Glucosidase and HMG-CoA Reductase Dual Inhibitor Improving Obesity and Metabolic Dysfunction in Vivo
by Wang, Kai and Bao, Li and Zhou, Nan and Zhang, Jinjin and Liao, Mingfang and Zheng, Zhongyong and Wang, Yujing and Liu, Chang and Wang, Jun and Wang, Lifeng and Wang, Wenzhao and Liu, ShuangJiang and Liu, Hongwei
Journal of medicinal chemistry, ISSN 0022-2623, 04/2018, Volume 61, Issue 8, pp. 3609 - 3625
Obesity - drug therapy | Microsomes, Liver - metabolism | Glycoside Hydrolase Inhibitors - therapeutic use | Male | Terpenes - toxicity | Glycoside Hydrolase Inhibitors - toxicity | Metabolic Syndrome - drug therapy | Anti-Obesity Agents - therapeutic use | Anti-Obesity Agents - toxicity | Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacokinetics | Lactones - chemical synthesis | Anti-Obesity Agents - pharmacokinetics | Hydroxymethylglutaryl CoA Reductases - metabolism | Lactones - pharmacokinetics | Glycoside Hydrolase Inhibitors - pharmacokinetics | Swine | Female | Terpenes - chemical synthesis | Hydroxymethylglutaryl-CoA Reductase Inhibitors - chemical synthesis | Hydroxymethylglutaryl-CoA Reductase Inhibitors - toxicity | Drug Stability | Mice, Inbred C57BL | Rats, Sprague-Dawley | Fatty Liver - drug therapy | Lactones - therapeutic use | Lactones - toxicity | Glycoside Hydrolase Inhibitors - chemical synthesis | Animals | Gastrointestinal Microbiome - drug effects | Terpenes - pharmacokinetics | Anti-Obesity Agents - chemical synthesis | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | Terpenes - therapeutic use | alpha-Glucosidases - metabolism | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Pharmacokinetics, metabolism, bioavailability, tissue distribution and excretion studies of 16α-hydroxycleroda-3, 13(14) Z -dien-15, 16-olide—a novel HMG-CoA reductase inhibitor
by Laxman, Tulsankar Sachin and Puttrevu, Santosh Kumar and Pradhan, Rajesh and Mishra, Anjali and Verma, Sarvesh and Chhonker, Yashpal S and Srivastava, Swarnim and Singh, Suriya P and Sashidhara, Koneni V and Bhatta, Rabi Sankar
Naunyn-Schmiedeberg's archives of pharmacology, ISSN 0028-1298, 9/2018, Volume 391, Issue 9, pp. 965 - 973
4655K-09 | Neurosciences | Excretion | Biomedicine | HMG-CoA reductase inhibitor | Tissue disposition | Bioavailability | Pharmacology/Toxicology | Metabolism | Life Sciences & Biomedicine | Pharmacology & Pharmacy | Science & Technology | Injections, Intravenous | Administration, Oral | Hydroxymethylglutaryl-CoA Reductase Inhibitors - blood | Biological Availability | Male | Diterpenes, Clerodane - urine | Rats, Sprague-Dawley | Tissue Distribution | Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacokinetics | Animals | Diterpenes, Clerodane - blood | Feces - chemistry | Hydroxymethylglutaryl-CoA Reductase Inhibitors - urine | Diterpenes, Clerodane - pharmacokinetics | Urine | Kidneys | HMG-CoA reductase inhibitors | Liver | Oral administration | Organs | Rats | Pharmacology | Conversion | Inhibitors | Metabolites | Rodents | Animal tissues | Hydroxymethylglutaryl-CoA reductase | Pharmacokinetics | Statins | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Pharmacokinetic-Pharmacodynamic Drug Interactions with HMG-CoA Reductase Inhibitors
by Williams D and Feely J
2002, Volume 41, Issue 5, 28
Simvastatin, drug interactions | Fibric acid derivatives, drug interactions | HMG CoA reductase inhibitors, drug interactions | Statins, drug interactions | Drug interactions | Pravastatin, drug interactions | Lovastatin, drug interactions | Atorvastatin, drug interactions | Nicotinic acid, drug interactions | Digoxin, drug interactions | Warfarin, drug interactions | Pharmacokinetic pharmacodynamic relationships | Fluvastatin, drug interactions | Cerivastatin, drug interactions | Pharmacotherapy | Internal Medicine | Medicine & Public Health | Pharmacology/Toxicology | Life Sciences & Biomedicine | Pharmacology & Pharmacy | Science & Technology | Biological and medical sciences | Medical sciences | General and cellular metabolism. Vitamins | Pharmacology. Drug treatments | Hyperlipidemias - metabolism | Humans | Hyperlipidemias - drug therapy | Cytochrome P-450 Enzyme System - metabolism | Biological Availability | Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacokinetics | Anticholesteremic Agents - pharmacokinetics | Animals | Anticholesteremic Agents - therapeutic use | Drug Interactions | Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacology | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | Anticholesteremic Agents - pharmacology | Index Medicus
Book Review
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Ethnic Variability in the Plasma Exposures of OATP1B1 Substrates Such as HMG‐CoA Reductase Inhibitors: A Kinetic Consideration of Its Mechanism
by Tomita, Y and Maeda, K and Sugiyama, Y
Clinical pharmacology and therapeutics, ISSN 0009-9236, 07/2013, Volume 94, Issue 1, pp. 37 - 51
Life Sciences & Biomedicine | Pharmacology & Pharmacy | Science & Technology | ATP Binding Cassette Transporter, Sub-Family G, Member 2 | Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage | Angiotensin Receptor Antagonists - pharmacokinetics | Fluorobenzenes - pharmacokinetics | Pyrimidines - administration & dosage | Humans | Liver - metabolism | Rosuvastatin Calcium | Biological Availability | Fluorobenzenes - administration & dosage | Sulfonamides - pharmacokinetics | Dose-Response Relationship, Drug | Tissue Distribution | Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacokinetics | Organic Anion Transporters - genetics | Ethnic Groups - genetics | ATP-Binding Cassette Transporters - genetics | Biological Transport | Pyrimidines - pharmacokinetics | Neoplasm Proteins - genetics | Solute Carrier Organic Anion Transporter Family Member 1b1 | Sulfonamides - administration & dosage | Angiotensin Receptor Antagonists - administration & dosage | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights